Terms ending in 2029
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,910,098 | Anti-VEGF Antibodies In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,329,709 | 5H-CYCLOPENTA[D]PYRIMIDINES as Akt Protein Kinase Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence | |
| US 9,328,091 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS In force · High confidence | Array Biopharma, Inc. | In force | High confidence | |
| US 9,365,642 | Methods and Compositions for Targeting Polyubiquitin In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 9,492,553 | Nemorubicin Metabolite and Analog Reagents, Antibody-Drug Conjugates and Methods In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,436,147 | Antibodies and Immunoconjugates and Uses Therefor In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,597,776 | Composition Comprising Antibody That Binds to Domain II of HER2 and Acidic Variants Thereof In force · Low confidence | Genentech, Inc. | In force | Low confidence | |
| US 12,110,341 | Composition Comprising Antibody That Binds to Domain II of HER2 and Acidic Variants Thereof In force · Low confidence | Genentech, Inc. | In force | Low confidence | |
| US 8,303,955 | Humanized ANTI-CD40 Antibodies and Their Methods of Use In force · High confidence | Seagen Inc. | In force | High confidence | |
| US 7,846,929 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | |
| 36 more term ends in 2029 · Pro | |||||
10 of 46 patents shown. Soonest term end first, then patent number.
Pro members see all 46.
34 of these are in force and held by Genentech, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.